Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Oct;5(10):598-9.
doi: 10.1038/ncpcardio1306. Epub 2008 Aug 5.

Bioabsorbable Drug-Eluting Stents: The Future of Coronary Angioplasty?


Bioabsorbable Drug-Eluting Stents: The Future of Coronary Angioplasty?

Carlos Macaya et al. Nat Clin Pract Cardiovasc Med. .


In the ABSORB trial, the feasibility of using a fully bioabsorbable everolimus-eluting stent (BVS; Abbott Vascular, Santa Clara, CA) in patients with ischemia and a single de novo coronary lesion was investigated. Some important concerns about the efficacy of this device were raised by this study. The in-stent late loss with the BVS (0.44 mm) was comparable to that seen with some drug-eluting stents currently on the market, and the late lumen loss was primarily due to reduction in stent area. Technical improvements aimed at definitively preventing late vessel recoil and negative remodeling, as well as clarification of the behavior of these devices with longer follow-up, are needed before fully bioabsorbable drug-eluting stents can be considered a therapeutic option for patients with coronary artery disease.

Similar articles

See all similar articles

Cited by 1 article

MeSH terms